Inviragen receives grants for dengue, chikungunya vaccines

The biotechnology company Inviragen announced on November 2 that it has received two grants totaling $488,958 from a recently established U.S. government program to fight dengue fever and chikungunya virus.

Inviragen, which predominantly develops vaccines for worldwide infectious diseases, received the grants as part of the U.S. government’s Qualifying Therapeutic Discovery Project Program. They were awarded for the company’s ongoing efforts to develop vaccines against the dengue and chikungunya viruses, according to

Inviragen is currently in the middle of testing DENVax, which is Inviragen’s developing dengue vaccine. DENVax is currently in two Phase I human clinical trials, reports. The biotech’s experimental chikungunya vaccine is currently undergoing preclinical testing.

“The Department of Health and Human Services recognized the potential public health impact of Inviragen’s dengue and chikungunya vaccines,” Dr. Dan Stinchcomb, Inviragen’s CEO, said, accorindg to “The funds will permit Inviragen to accelerate our clinical and preclinical vaccine studies.”

The Qualifying Therapeutic Discovery Project Program was established in 2010 by the Patient Protection and Affordable Care Act. It provides tax credits and grants to smaller biotechnology firms with 250 employees or fewer. It seeks out those that show significant potential to make medical breakthroughs, create or sustain employment, and increase U.S. competitiveness globally.